Mikawa K, Maekawa N, Nishina K, Takao Y, Yaku H, Obara H
Dept of Anaesthesiology, Kobe University School of Medicine, Japan.
Eur Respir J. 1993 Nov;6(10):1563-6.
The efficacy of treatment with exogenous surfactant has been reported in children with respiratory failure due to severe pneumonia. Its effect in adults with similar features has not been established. We therefore administered 240 mg of surfactant to a 71 year old man, who had developed right lower lobe pneumonia and hypoxaemia following abdominal aortic surgery. After this treatment, the patient's oxygenation, evaluated by arterial oxygen tension/fraction of inspired oxygen (PaO2/FIO2) ratio during artificial ventilation, gradually improved, and ventilator settings could be reduced whilst maintaining PaO2 at the appropriate level. Although the precise mechanism by which surfactant improves respiratory failure due to pneumonia is unclear, administration of the drug may have overcome a quantitative deficiency of endogenous surfactant attributable to the antagonistic effect of pulmonary exudates and reduced production following damage to type II pneumocytes. The present case provides an indirect suggestion of a possible causal relationship between the improvement of oxygenation and administration of surfactant in adult respiratory failure caused by pneumonia.
外源性表面活性剂治疗重症肺炎所致呼吸衰竭儿童的疗效已有报道。其对具有相似特征的成人患者的疗效尚未明确。因此,我们对一名71岁男性患者给予了240毫克表面活性剂,该患者在腹主动脉手术后出现右下叶肺炎和低氧血症。治疗后,通过人工通气期间的动脉血氧分压/吸入氧分数(PaO2/FIO2)比值评估,患者的氧合逐渐改善,并且在将PaO2维持在适当水平的同时,可以降低呼吸机设置。尽管表面活性剂改善肺炎所致呼吸衰竭的确切机制尚不清楚,但给药可能克服了由于肺渗出物的拮抗作用和II型肺细胞损伤后产生减少导致的内源性表面活性剂的定量不足。本病例间接提示了在成人肺炎所致呼吸衰竭中,氧合改善与表面活性剂给药之间可能存在因果关系。